Code | CSB-RA798840A0HU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IHC | 1:50-1:200 |
The production of the recombinant TERT antibody depended on Single B Cell technology. There are 3 main steps in the production: 1, Isolation of single B cells. High-throughput methods could be used to obtain the efficient identification and desired specificity of B cells. 3, Single B cell antibody sequencing and cloning. In this step, the antibody gene sequence of TERT was obtained and introduced to plasmids, which then would be transferred to mammalian cells for in vitro expression of the TERT antibody. 3, Screening of antibodies. The target antibody was obtained in this step. And it has been validated in ELISA, IHC.
TERT, a catalytic subunit of telomerase, plays a key role in cancer formation. It maintains telomere length to ensure chromosomal stability, thus allowing cells to avoid senescence. Mutations in the TERT gens can affect telomerase activity and telomere length, resulting in serious clinical manifestations such as bone marrow failure syndromes and a significant increase in cancer incidence. It has been demonstrated that enhanced TERT expression causes telomerase activity to be restored, indicating TERT transcriptional control as a critical component in diseases such as aging and cancer.
There are currently no reviews for this product.